Press Release: ASH: Rilzabrutinib Demonstrated Significant Patient Benefit In The First Positive Phase 3 Study Of A BTK Inhibitor In ITP
Press Release: ASH: Rilzabrutinib Demonstrated Significant Patient Benefit In The First Positive Phase 3 Study Of A BTK Inhibitor In ITP . (MENAFN - GlobeNewsWire - Nasdaq) ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP   Pivotal phase 3 data show rapid and ...
América - MenaFN
Jordania
https://menafn.com/images/Menafn_SmallLogo.jpg
https://menafn.com/1108967025/Press-Release-ASH-Rilzabrutinib-Demonstrated-Significant-Patient-Benefit-In-The-First-Positive-Phase-3-Study-Of-A-BTK-Inhibitor-In-ITP
2024-12-07
rss
(MENAFN - GlobeNewsWire - Nasdaq) ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP   Pivotal phase 3 data show rapid and ...
Press Release: ASH: Rilzabrutinib Demonstrated Significant Patient Benefit In The First Positive Phase 3 Study Of A BTK Inhibitor In ITP